ACR, American College of Rheumatology; CRP, C-reactive protein; DMARD, diseasemodifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; PGA, patient global assessment; PhGA, physician global assessment; SJC, swollen joint count; TJC, tender joint count; TNFi, tumour necrosis factor inhibitor; TNFi-naive, patients who had never received TNFi therapy; TNFiprevious use, patients who had discontinued TNFi therapy for >2 months before baseline (washout period); TNFi-recent use, patients who had discontinued TNFi therapy for ≤2 months before baseline (no washout period); VAS, visual analogue scale.
ACR, American College of Rheumatology; CRP, C-reactive protein; DMARD, diseasemodifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; PGA, patient global assessment; PhGA, physician global assessment; SJC, swollen joint count; TJC, tender joint count; TNFi, tumour necrosis factor inhibitor; TNFi-naive, patients who had never received TNFi therapy; TNFiprevious use, patients who had discontinued TNFi therapy for >2 months before baseline (washout period); TNFi-recent use, patients who had discontinued TNFi therapy for ≤2 months before baseline (no washout period); VAS, visual analogue scale.
Supplementary Figure S1
Summary of patient disposition. AE, adverse event; DMARD, disease-modifying anti-rheumatic drug; ITT, intent-to-treat; TCZ, tocilizumab; TNFi, tumour necrosis factor inhibitor; TNFi-naive, patients who had never received TNFi therapy; TNFiprevious use, patients who had discontinued TNFi therapy for >2 months before baseline (washout period); TNFi-recent use, patients who had discontinued TNFi therapy for ≤2 months before baseline (no washout period).
Patients not enrolled* n = 310 Violation of entry criteria: n = 144 † Other reasons: n = 166
Patients screened N = 1,993
Patients enrolled n = 1,683
Patients who did not receive study medication n = 2
ITT and safety population: overall, n = 1,681 TNFi-naive, n = 976 TNFi-previous use, n = 298
TNFi-recent use, n = 407
Patients who completed the study: overall, n = 1466 TNFi-naive, n = 876 TNFi-previous use, n = 245
TNFi-recent use, n = 345
Patients who discontinued the study: overall, n = 215 TNFi-naive, n = 100 (Safety: n = 42; non-safety: n = 58) TNFi-previous use, n = 53 (Safety: n = 18; non-safety: n =35) TNFi-recent use, n = 62 (Safety: n = 20; non-safety: n =42) † Most common criteria leading to exclusion (each contributing to >5% of exclusions): 
Sample Size
The following considerations justify the sample size of approximately 1,500 patients from the clinical point of view. We assume that at least 1,200 patients (i.e. 80% of the recruited patients) will conclude the study, providing a sample of patients with full exposure to the study drug from which the following can be expected:
-Assuming that a specific event (such an AE, treatment discontinuation, or transaminase elevation) occurs in 5% of patients in the study, the 95% CI around that incidence will extend from 3.8% to 6.2%. If the event occurs in 10% of patients, the CI will extend from 8.3% to 11.7% -A TCZ-associated AE occurring in 1/1,000 patients would have a 70% chance to occur at least once in the patient population, and an event occurring in 1/522 patients would have a 90% chance to be detected
Results

Patient-Reported Outcomes
Health Assessment Questionnaire-Disability Index (HAQ-DI) clinical remission (HAQ-DI <0.5) was achieved by 31.5% of patients at week 24, at which time TNFi-recent patients had 
